Folate metabolic pathway single nucleotide polymorphisms: a predictive pharmacogenetic marker of methotrexate response in Indian (Asian) patients with rheumatoid arthritis-Reference-Cited by-同舟云学术

Folate metabolic pathway single nucleotide polymorphisms: a predictive pharmacogenetic marker of methotrexate response in Indian (Asian) patients with rheumatoid arthritis

Published:2015-12 Issue:18 Volume:16 Page:2019-2034
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Ghodke-Puranik Yogita¹²,Puranik Amrutesh S¹³,Shintre Pooja⁴⁵,Joshi Kalpana⁴,Patwardhan Bhushan¹,Lamba Jatinder⁶,Niewold Timothy B²,Chopra Arvind⁷

Affiliation:

1. Interdisciplinary School of Health Sciences, University of Pune, Pune 411007, India

2. Department of Immunology & Division of Rheumatology, Mayo Clinic, Rochester, MN 55901, USA

3. Center for Aging, Mayo Clinic, Rochester, MN 55901, USA

4. Department of Biotechnology, Sinhgad College of Engineering, Pune 411041, India

5. School of Anatomy, Physiology & Human Biology, University of Western Australia, Australia

6. University of Florida, Gainesville, FL 32610, USA

7. Centre for Rheumatic Diseases, Pune 411001, India

Abstract

Aim: We evaluated the pharmacogenetic influence of genetic polymorphisms in folate pathway genes in Indian rheumatoid arthritis patients receiving methotrexate (MTX). Patients & methods: Twelve polymorphisms within nine folate pathway genes were analyzed for association with MTX response in 322 Indian rheumatoid arthritis (RA) patients and MTX pharmacokinetics in 94 RA patients. Results: Polymorphisms in GGH, SHMT1 and TS were associated with MTX-related adverse events while SNPs in MTHFR and RFC1/SLC19A1 were associated with MTX efficacy. TS5′UTR and SHMT1 polymorphisms were associated with higher plasma levels of MTX. Conclusion: Polymorphisms in folate-MTX pathway genes contribute to MTX response and affect MTX concentrations in Indian RA patients. A toxicogenetic index could identify patients who develop adverse events to MTX.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs.15.145

Reference48 articles.

1. Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases

2. Methotrexate in rheumatoid arthritis: experience and recommendations from the 3E initiative

3. Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment

4. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

5. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relationship between the efficacy and adverse effects of methotrexate and gene polymorphism;Egyptian Journal of Medical Human Genetics;2024-08-04

2. Genetic polymorphisms and clinical parameters associated with renal toxicity in Thai hematologic malignancy patients receiving high dose methotrexate;Scientific Reports;2024-04-27

3. The effects of genetic polymorphism on toxicity and pharmacokinetics of methotrexate in Egyptian adult patients with leukaemia or lymphoma;Xenobiotica;2024-02-07

4. The impact of folate pathway variants on the outcome of methotrexate therapy in rheumatoid arthritis patients;Clinical Rheumatology;2024-02-05

5. Indigenous Knowledge and Phytochemistry: Deciphering the Healing Power of Herbal Medicine;Reference Series in Phytochemistry;2024